
Gustavo A. Rosario Benitez
Examiner (ID: 599, Phone: (571)270-7888 , Office: P/2838 )
| Most Active Art Unit | 2838 |
| Art Unit(s) | 2838 |
| Total Applications | 811 |
| Issued Applications | 625 |
| Pending Applications | 91 |
| Abandoned Applications | 129 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18739656
[patent_doc_number] => 20230348618
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS
[patent_app_type] => utility
[patent_app_number] => 18/055932
[patent_app_country] => US
[patent_app_date] => 2022-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18055932
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/055932 | COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS | Nov 15, 2022 | Pending |
Array
(
[id] => 18376015
[patent_doc_number] => 20230151097
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => ANTI-CD3-BINDING DOMAINS AND ANTIBODIES COMPRISING THEM, AND METHODS FOR THEIR GENERATION AND USE
[patent_app_type] => utility
[patent_app_number] => 18/054588
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71256
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054588
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054588 | ANTI-CD3-BINDING DOMAINS AND ANTIBODIES COMPRISING THEM, AND METHODS FOR THEIR GENERATION AND USE | Nov 10, 2022 | Pending |
Array
(
[id] => 18612341
[patent_doc_number] => 20230279073
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 18/052037
[patent_app_country] => US
[patent_app_date] => 2022-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11234
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052037
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/052037 | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEMATOLOGIC NEOPLASMS AND OTHER CANCERS | Nov 1, 2022 | Pending |
Array
(
[id] => 18537522
[patent_doc_number] => 20230242619
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => COMPOSITIONS COMPRISING A TN3 SCAFFOLD AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/051704
[patent_app_country] => US
[patent_app_date] => 2022-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49108
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051704
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/051704 | COMPOSITIONS COMPRISING A TN3 SCAFFOLD AND METHODS OF USING THE SAME | Oct 31, 2022 | Pending |
Array
(
[id] => 18916733
[patent_doc_number] => 11879003
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-23
[patent_title] => Methods for increasing T-cell function
[patent_app_type] => utility
[patent_app_number] => 18/048621
[patent_app_country] => US
[patent_app_date] => 2022-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 23082
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18048621
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/048621 | Methods for increasing T-cell function | Oct 20, 2022 | Issued |
Array
(
[id] => 18613619
[patent_doc_number] => 20230280355
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/046865
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046865
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046865 | METHODS FOR ASSAYING T-CELL DEPENDENT BISPECIFIC ANTIBODIES | Oct 13, 2022 | Pending |
Array
(
[id] => 18692589
[patent_doc_number] => 20230322895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => T CELL RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 18/046408
[patent_app_country] => US
[patent_app_date] => 2022-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15478
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046408
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046408 | T CELL RECEPTORS | Oct 12, 2022 | Pending |
Array
(
[id] => 18449373
[patent_doc_number] => 20230190649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/045946
[patent_app_country] => US
[patent_app_date] => 2022-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14191
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 145
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045946
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045946 | LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES | Oct 11, 2022 | Pending |
Array
(
[id] => 18451573
[patent_doc_number] => 20230192851
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => ANTI-CD3 ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME
[patent_app_type] => utility
[patent_app_number] => 17/958995
[patent_app_country] => US
[patent_app_date] => 2022-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7955
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 213
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17958995
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/958995 | ANTI-CD3 ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT COMPRISING SAME | Oct 2, 2022 | Pending |
Array
(
[id] => 18376030
[patent_doc_number] => 20230151112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE
[patent_app_type] => utility
[patent_app_number] => 17/933879
[patent_app_country] => US
[patent_app_date] => 2022-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32546
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17933879
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/933879 | IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | Sep 20, 2022 | Pending |
Array
(
[id] => 18786091
[patent_doc_number] => 20230374080
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => METHODS FOR CONTROL OF AN INFECTIVE DISEASE WITH A VACCINE
[patent_app_type] => utility
[patent_app_number] => 17/948406
[patent_app_country] => US
[patent_app_date] => 2022-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7002
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 144
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17948406
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/948406 | METHODS FOR CONTROL OF AN INFECTIVE DISEASE WITH A VACCINE | Sep 19, 2022 | Pending |
Array
(
[id] => 20264176
[patent_doc_number] => 12435152
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-07
[patent_title] => Humanized BCMA antibody and BCMA-CAR-T cells
[patent_app_type] => utility
[patent_app_number] => 17/930662
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 11
[patent_no_of_words] => 145
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 167
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930662
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930662 | Humanized BCMA antibody and BCMA-CAR-T cells | Sep 7, 2022 | Issued |
Array
(
[id] => 20264176
[patent_doc_number] => 12435152
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-07
[patent_title] => Humanized BCMA antibody and BCMA-CAR-T cells
[patent_app_type] => utility
[patent_app_number] => 17/930662
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 11
[patent_no_of_words] => 145
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 167
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930662
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930662 | Humanized BCMA antibody and BCMA-CAR-T cells | Sep 7, 2022 | Issued |
Array
(
[id] => 20343174
[patent_doc_number] => 12466896
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-11
[patent_title] => Anti-CD3 antibodies and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/930018
[patent_app_country] => US
[patent_app_date] => 2022-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 170
[patent_figures_cnt] => 171
[patent_no_of_words] => 216261
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930018
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930018 | Anti-CD3 antibodies and methods of use | Sep 5, 2022 | Issued |
Array
(
[id] => 18536150
[patent_doc_number] => 20230241238
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => BIFUNCTIONAL POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/929682
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8902
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929682
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/929682 | BIFUNCTIONAL POLYPEPTIDES | Sep 1, 2022 | Pending |
Array
(
[id] => 18221853
[patent_doc_number] => 20230060847
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/898208
[patent_app_country] => US
[patent_app_date] => 2022-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11136
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17898208
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/898208 | ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES | Aug 28, 2022 | Pending |
Array
(
[id] => 18739655
[patent_doc_number] => 20230348617
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETED TO PSCA
[patent_app_type] => utility
[patent_app_number] => 17/820440
[patent_app_country] => US
[patent_app_date] => 2022-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12329
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820440
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/820440 | CHIMERIC ANTIGEN RECEPTORS TARGETED TO PSCA | Aug 16, 2022 | Pending |
Array
(
[id] => 18511431
[patent_doc_number] => 20230227581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => HETERODIMERIC ANTIBODIES THAT BIND ENPP3 AND CD3
[patent_app_type] => utility
[patent_app_number] => 17/817334
[patent_app_country] => US
[patent_app_date] => 2022-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45887
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817334
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/817334 | HETERODIMERIC ANTIBODIES THAT BIND ENPP3 AND CD3 | Aug 2, 2022 | Pending |
Array
(
[id] => 18511431
[patent_doc_number] => 20230227581
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => HETERODIMERIC ANTIBODIES THAT BIND ENPP3 AND CD3
[patent_app_type] => utility
[patent_app_number] => 17/817334
[patent_app_country] => US
[patent_app_date] => 2022-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45887
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817334
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/817334 | HETERODIMERIC ANTIBODIES THAT BIND ENPP3 AND CD3 | Aug 2, 2022 | Pending |
Array
(
[id] => 18497461
[patent_doc_number] => 20230220101
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => Methods and Antibody Compositions for Tumor Treatment
[patent_app_type] => utility
[patent_app_number] => 17/875295
[patent_app_country] => US
[patent_app_date] => 2022-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38504
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17875295
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/875295 | Methods and Antibody Compositions for Tumor Treatment | Jul 26, 2022 | Pending |